Pipeline

Program

Active Compound

Pre-Clinical

Phase I

Phase II/III

NDA Filing

Enolen®

Low to Intermediate Risk Localized Prostate Cancer

Active Compound: Enzalutamide Implant

Pre-Clinical

Phase I

Phase II/III

NDA Filing

EP-001 Pre-prostatectomy PoC
EP-001 Pre-prostatectomy PoC

Pamolen™

Intermediate to High Risk
Localized Prostate Cancer

Active Compound: PARP Inhibitor Combinations

Pre-Clinical

Phase I

Phase II/III

NDA Filing

IND 2H/26
IND 2H/26

Biolen®

Benign Prostatic
Hyperplasia (BPH)*

Active Compound: Bicalutamide Implant

Pre-Clinical

Phase I

Phase II/III

NDA Filing

CP-001 Pre-prostatectomy PoC
CP-001 Pre-prostatectomy PoC
CP-002 Combination with Radiation PoC
CP-002 Combination with Radiation PoC

*Biolen completed a Phase 1 clinical study in early stage prostate cancer; will go forward in BPH